AF
MLYS icon

Allworth Financial’s Mineralys Therapeutics MLYS Stock Holding History

Allworth Financial’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.73K Sell
101
-253
-71% -$6.94K ﹤0.01% 4386
2026
Q1 		$9.59K Buy
354
+135
+62% +$3.96K ﹤0.01% 3539
2025
Q4 		$7.95K Buy
219
+175
+398% +$7.02K ﹤0.01% 3422
2025
Q3 		$1.67K Buy
44
+10
+29% +$216 ﹤0.01% 4085
2025
Q2 		$461 Sell
34
-56
-62% -$811 ﹤0.01% 4158
2025
Q1 		$1.27K Buy
90
+62
+221% +$713 ﹤0.01% 3383
2024
Q4 		$286 Sell
28
-105
-79% -$1.37K ﹤0.01% 3722
2024
Q3 		$1.61K Hold
133
– – ﹤0.01% 3048
2024
Q2 		$1.76K Buy
+133
New +$1.68K ﹤0.01% 2980

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Allworth Financial's MLYS Position: Q2 2026 in Review

Allworth Financial reduced its Mineralys Therapeutics (MLYS) stake by 71% in Q2 2026, selling an estimated $6.94K and leaving 101 shares worth $2.73K. The position accounts for ﹤0.01% of the portfolio, ranked #4386.

Allworth Financial first reported a position in MLYS in Q2 2024 and has held it in 9 quarters since. The position peaked at $9.59K in Q1 2026. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Allworth Financial held 101 shares of Mineralys Therapeutics worth $2.73K as of Q2 2026.
  • Allworth Financial sold 253 Mineralys Therapeutics shares in Q2 2026, an estimated $6.94K.
  • Mineralys Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4386 holding.
  • Allworth Financial first reported a position in Mineralys Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Allworth Financial's Mineralys Therapeutics position peaked at $9.59K in Q1 2026.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.